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Traumatic brain injury (TBI) in children can result in long-lasting social, cognitive, and
neurological impairments. In adults, TBI can lead to endocrinopathies (endocrine system
disorders), but this is infrequently reported in children. Untreated endocrinopathies can
elevate risks of subsequent health issues, such that early detection in pediatric TBI
survivors can initiate clinical interventions. To understand the risk of endocrinopathies
following pediatric TBI, we identified patients who had experienced a TBI and
subsequently developed a new-onset hypothalamic regulated endocrinopathy (n= 498).
We hypothesized that pediatric patients who were diagnosed with a TBI were at higher
risk of being diagnosedwith a central endocrinopathy than thosewithout a prior diagnosis
of TBI. In our epidemiological assessment, we identified pediatric patients enrolled in
the Arizona Health Care Cost Containment System (AHCCCS) from 2008 to 2014 who
were diagnosed with one of 330 TBI International Classification of Diseases (ICD)-9
codes and subsequently diagnosed with one of 14 central endocrinopathy ICD-9 codes.
Additionally, the ICD-9 code data from over 600,000 Arizona pediatric patients afforded
an estimate of the incidence, prevalence, relative risk, odds ratio, and number needed
to harm, regarding the development of a central endocrinopathy after sustaining a
TBI in Arizona Medicaid pediatric patients. Children with a TBI diagnosis had 3.22
times the risk of a subsequent central endocrine diagnosis compared with the general
population (±0.28). Pediatric AHCCCS patients with a central endocrine diagnosis had
3.2-fold higher odds of a history of a TBI diagnosis than those without an endocrine
diagnosis (±0.29). Furthermore, the number of patients with a TBI diagnosis for one
patient to receive a diagnosis of a central endocrine diagnosis was 151.2 (±6.12).
Female subjects were more likely to present with a central endocrine diagnosis after
a TBI diagnosis compared to male subjects (64.1 vs. 35.9%). These results are the
first state-wide epidemiological study conducted to determine the risk of developing a
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hypothalamic-pituitary disorder after a TBI in the pediatric population. Our results
contribute to a body of knowledge demonstrating a TBI etiology for idiopathic endocrine
disorders, and thus advise physicians with regard to TBI follow-up care that includes
preventive screening for endocrine disorders.
Keywords: traumatic brain injury, pediatrics, endocrine dysfunction, concussion, adolescence, hypopituitarism,
puberty, head injury
INTRODUCTION
In children, traumatic brain injuries (TBIs) account for over
812,000 emergency department visits every year and are a
leading cause of childhood mortality and morbidity in the
United States (1). A TBI can be defined as a non-degenerative,
non-congenital insult to the brain from an external mechanical
force, potentially leading to permanent or temporary impairment
of cognitive, physical, and psychosocial functions, with an
associated diminished or altered state of consciousness. Those
who survive pediatric TBI are at risk for poor developmental and
functional outcomes later in life. Very young children may be
particularly vulnerable to the effects of TBI as the brain is under
continuous development throughout childhood (2). Pediatric
survivors of TBI are at increased risk for worse behavioral,
social, and academic outcomes compared to their peers (3–
6). Moreover, pediatric survivors of TBI show high incidence
of health issues including pain, cardiovascular, and metabolic
disorders (2). In particular, TBI precede the development of
endocrinopathies, or dysfunction of the endocrine system, as
reported in adults (7–11). Furthermore, both early and late
endocrine changes can occur after TBI in pediatric patients (12).
These alterations include acute alterations in the hypothalamic-
pituitary-adrenal axis, antidiuretic hormone regulation, growth
hormone (GH) deficiency, disturbances in puberty, central
hypothyroidism [hypothyroidism due to insufficient stimulations
by thyroid stimulating hormone (TSH) of an otherwise normal
thyroid gland], and elevated prolactin, which can each be
temporary or permanent (12, 13). The goal of this study was
to better understand the epidemiology of TBI and subsequent
endocrinopathy in the pediatric population. We hypothesized
that pediatric patients who were diagnosed with a TBI were at
greater risk of being diagnosed with a hypothalamic-pituitary
disorder than those without a prior diagnosis of TBI.
In adults, the prevalence of endocrinopathy following TBI is
common, with the most prevalent disorder being GH deficiency
(7, 10, 14, 15). A recent meta-analysis that included data from
2,756 adult TBI patients reported a 32% overall prevalence of at
least one endocrine diagnosis after TBI (8). Similarly, a previous
meta-analysis that included data of 1,203 adult TBI patients,
reported a 27.8% overall prevalence of at least one endocrine
dysfunction, with 6.2% of patients having more than one
endocrine dysfunction post-TBI (16). However, the prevalence of
endocrine dysfunction after TBI in the pediatric population is less
clear. Between 1977 and 2004, only a total of 20 pediatric cases
of hypopituitarism after TBI were reported. Across these reports,
the interval between TBI and endocrine diagnosis ranged from
1 to 42 years (17), which highlights the lack of recorded data in
this domain. The prevalence of endocrine dysfunction following
a TBI in pediatric studies ranged from 5 to 57% and up to 86%
in studies including hyperprolactinemia as an abnormality (17).
However, more recent studies show that endocrine dysfunction
may be a common occurrence following pediatric TBI (18–23).
These existing reports differ in the eligible pediatric population,
inclusion criteria, and methodological design, in addition to
varied hormonal assessment, baseline profile, and dynamic tests,
sometimes in subsets of subjects (24–30), which compromise
the ability to compare between studies. Thus, there is a need to
better understand whether a TBI diagnosis is a risk factor for
a subsequent endocrine diagnosis in the pediatric population.
Here, we present the epidemiology of central endocrine diagnoses
following a patient’s first TBI diagnosis in the Arizona pediatric
population, with a focus on male/female patients and time
between TBI and endocrine diagnoses.
METHODS
Inclusion and Exclusion Criteria
We used de-identified patient records from the Arizona Health
Care Cost Containment System (AHCCCS), the Medicaid
program for the state of Arizona. We queried the AHCCCS
database for patients (≤18 years old) with a TBI diagnosis
followed by a central endocrine diagnosis after the initial TBI
diagnosis (see Appendices 1, 2 for International Classification of
Diseases (ICD)-9 diagnoses codes for TBI and endocrinopathies,
respectively). Based on clinical relevance and inputs from
care providers, TBI diagnoses were restricted to a total of
330 diagnoses of concussion, skull fracture, cerebral injury or
hemorrhage, and head injury; cerebrovascular diseases were
excluded. Central endocrine diagnoses were restricted to 14
diagnoses of the pituitary, the hypothalamus, diabetes insipidus,
and puberty, excluding premorbid diabetes, toxic exposure, and
circadian rhythm disorders. Inclusion/exclusion criteria for the
research study primarily identified cases of TBI followed by
an endocrine diagnosis, with both diagnoses having occurred
before or at the age of 18. In addition, we included only
patients who were continuously enrolled in AHCCCS with no
more than a 30-day gap in coverage per year, in order to
assure that missed diagnoses were minimized. The number of
patients found in these records was sufficient to conduct an
epidemiological study to determine the relationships between
age and gender (only male and female) of patients with
a TBI diagnosis and subsequent endocrine diagnosis. The
inclusion/exclusion criteria for the population is presented in
Table 1. The study protocol was reviewed and approved by the
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TABLE 1 | Inclusion/exclusion criteria for the sample population.
Inclusion criteria
Age 0 ≤ 18 years
Located in Arizona
Enrolled in AHCCCS Medicaid from 2008 to 2014 without a lapse >30 days
Diagnosis of TBI
Diagnosis of an endocrine disorder after the TBI diagnosis
All diagnoses prior to or at the age of 18
Patients diagnosed with a TBI prior to or at the age of 18, without an
endocrine disorder
Patients diagnosed with an endocrine disorder prior to or at the age of 18,
without a TBI
Exclusion criteria
Diagnosis of an endocrine disorder prior to TBI
AHCCCS, Arizona Health Care Cost Containment Service; TBI, Traumatic Brain Injury.
Phoenix Children’s Hospital Institutional Review Board (IRB 15-
021) and deferred by the University of Arizona and Arizona
State University.
Data Analysis
To evaluate the risk of endocrine diagnosis after TBI diagnosis,
a limited data set with ICD-9 diagnosis and billing codes was
extracted for individual patients in the sample. Demographic
data and care delivery dates populated four cohorts (see
contingency matrix in Table 2): patients diagnosed with TBI
and subsequent endocrine disorder (TBI+, Endo+; A), with
TBI and without endocrine disorder (TBI+, Endo–; B), without
TBI and with endocrine disorder (TBI–, Endo+; C), and with
neither TBI nor endocrine diagnoses (TBI–, Endo–; D). Based
on the contingency table and demographic data, calculations
produced the prevalence, incidence, relative risk, odds ratio,
attributable risk, and number needed to harm of endocrine
diagnosis after TBI diagnosis stratified by age and male/female
patients. Data pre-processing and analyses were performed using
Python (version 3.7.3). Prevalence was calculated as the number
of TBI patients with an endocrine diagnosis divided by those
TBI patients without an endocrine diagnosis for each year (A/C).
Incidence rate was calculated as the number of new cases per
year of endocrine diagnoses in TBI patients divided by the
cumulative population of TBI patients
(
A/(A+ B)
)
. Relative risk
was calculated as the ratio of endocrine diagnoses in subjects
with and without TBI
(
A
(A+B)
/ C
(C+D)
)
. Odds ratio was calculated
as the ratio of patients with endocrine diagnoses and TBI to
those without TBI as a fraction of patients without endocrine
diagnoses and TBI to those without TBI
(
A
C /
B
D
)
. Attributable
risk was calculated as the difference in risk between patients
with TBI and those without TBI
(
A
A+B −
C
C+D
)
. Number needed
to harm was calculated as the inverse of the attributable risk(
1
Attributable Risk
)
. Epidemiological calculations were performed
for each year, averaged over the 7 years. Prevalence of TBI
and endocrine dysfunction are reported as mean and 90%
confidence interval.
TABLE 2 | Contingency table of sample populations for 2008–2014.
TBI+ TBI–
Year Endo+ Endo– Endo+ Endo–
2008 144 15,238 1,334 568,645
2009 154 16,919 1,585 646,008
2010 191 20,389 1,945 606,738
2011 220 20,906 2,024 622,756
2012 221 22,597 2,168 629,391
2013 223 22,153 2,237 616,052
2014 232 22,353 2,137 657,512
Contingency table of the sample populations used in this study. The table shows the
database population for each year included in the analysis. TBI+, traumatic brain injury
diagnosis present; TBI–, TBI diagnosis absent; Endo+, central endocrine diagnosis
present; Endo–, central endocrine diagnosis absent.
TABLE 3 | Prevalence of hypothalamic-pituitary disorder after a TBI diagnosis for
male subjects and female subjects and across age ranges.
TBI+, Endo+
Percent (n) Prevalence
Total 100.00% (498) 0.103
Male 35.94% (179) 0.278
Female 64.06% (319) 0.758
Age range Prevalence
0–0.9 years 0.042
1–1.9 years 0.046
2–2.9 years 0.061
3–3.9 years 0.072
4–4.9 years 0.104
5–5.9 years 0.153
6–6.9 years 0.151
7–7.9 years 0.213
8–8.9 years 0.203
9–9.9 years 0.188
10–10.9 years 0.167
11–11.9 years 0.163
12–12.9 years 0.128
13–13.9 years 0.109
14–14.9 years 0.152
15–15.9 years 0.104
16–16.9 years 0.091
17–17.9 years 0.069
RESULTS
Prevalence of TBI and Endocrine
Dysfunction Stratified by Age
The AHCCCS provided care for an average of 643,212 (±19,097
at CI of 90%) pediatric patients per year for analysis. From the
275,781 unique patients with either a TBI or central endocrine
diagnosis, there were 498 unique patients who were diagnosed
with a TBI and a subsequent endocrine diagnosis between 2008
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FIGURE 1 | Pediatric patients with a traumatic brain injury (TBI) who were diagnosed with a hypothalamic-pituitary disorder showed the highest prevalence in ages
7–11. (A) Patients (n = 498) with a TBI and subsequent endocrine diagnosis were indexed by age. Here, we sorted all patients of our group of interest by age with
patient index referring to the fraction of the total. The black line represents the age of each patient when they were diagnosed with a TBI, and the dot tracking along
the x-axis from the line indicates the subsequent onset of their first endocrine diagnosis. (B) Prevalence of an endocrine diagnosis after a TBI stratified by age at the
endocrine diagnosis. Here, prevalence was calculated as the number of TBI patients with an endocrine diagnosis divided by those TBI patients without an endocrine.
Children aged 7–11 years had the highest prevalence of an endocrine disorder diagnosis after a TBI diagnosis compared to other age groups.
and 2014, with an annual average of 197.9 (±22.3 at CI of 90%)
unique patients within each year. A total of 107,458 children were
diagnosed with a TBI before or at the age of 18 years.
The 498 patients with a TBI and subsequent endocrine
diagnosis were indexed by age to show age at TBI and age at
endocrine diagnosis (Figure 1A). The 18-year upper age limit
for both TBI and endocrine diagnosis sets an arbitrary ceiling
effect on the data. The overall prevalence for an endocrine
diagnosis after TBI was 0.103 (±0.003 at CI of 90%), with the
highest prevalence of an endocrine disorder diagnosis after a
TBI diagnosis occurring in the age range of 7–11 years old
(Figure 1B). The overall incidence was 0.0014 (±0.0002 at CI of
90%). We calculated a relative risk of 3.22 (±0.29 at CI of 90%),
and an odds ratio of 3.24 (±0.29 at CI of 90%), indicating that
patients exposed to pediatric TBI had about 3 times the risk of a
central endocrine diagnosis compared to the general population.
We observe an average number needed to harm of 151.19 (±6.12
at CI of 90%), meaning that for every 151 children diagnosed with
a TBI, one would have a hypothalamic-pituitary disorder.
Male/Female Differences With Age
The AHCCCS dataset contained binary entries for male and
female as entered by the health care facility, which were used to
calculate prevalence and incidence. Table 3 shows the prevalence
of hypothalamic-pituitary disorder after a TBI diagnosis for male
subjects and female subjects across age ranges. In the sample
of children with a TBI diagnosis followed by an endocrine
diagnosis, female individuals (n = 319) outnumbered male
individuals (n = 179). However, the prevalence of an endocrine
diagnosis after a TBI diagnosis in female patients (0.758) was
almost three times the prevalence in male patients (0.278;
Table 3). The greatest number of TBIs with subsequent endocrine
diagnoses in female patients occurred at <2 and 5–8 years
of age, whereas male patients had the most between 8 and
12 years of age (Figure 2A). Regardless, both male subjects
and female subjects had a high rate of endocrine diagnoses
between 7 and 15 years of age (Figure 2A). By 4-year age
band, the incidence associated with the age of an endocrine
diagnosis differed between female subjects and male subjects,
where female subjects showed higher overall incidence and at
younger ages than male subjects (Figure 2B). The time gap
between TBI diagnosis and endocrine diagnosis differed between
male and female patients (Figure 2C). Both male and female
patients were weighted toward an endocrine diagnosis within
2 years of TBI, with the bulk of female patients receiving the
diagnosis early.
Predominant ICD-9 Codes Used and
Diagnoses Over the Years
Table 4 shows the frequency and the number of patients for
each of the 14 endocrine-related ICD-9 codes analyzed in the
study, and for the 10 most frequent TBI-related ICD-9 codes
reported in the database. The predominant TBI diagnosis code
identified in the sample was 959.01 (Head Injury: Unspecified)
which comprised ∼64% of the subjects. Of note, 15% of subjects
had concussion (850.X) TBI diagnosis codes. The predominant
endocrine disorder code, based on the number of subjects, found
in the current study were 259.1 (Precocious sexual development
and puberty; not elsewhere classified) which comprised ∼59%
of the subjects followed by 253.3 (Pituitary dwarfism/GH
deficiencies) which comprised 9% of subjects. The substantial
number of unspecified head injury diagnostic codes (959.01)
prevented a meaningful analysis between TBI and endocrine
disorder diagnoses.
DISCUSSION
This is the first study to determine the epidemiology of new-onset
central endocrinopathies after TBI in the pediatric population
in Arizona. Our analyses indicated an increased risk of a
hypothalamic-pituitary disorder for patients with a history of
pediatric TBI diagnosis. We observed important male/female
differences, where female patients exhibited a higher incidence
peaking at an earlier age range compared to male patients, and
with female subjects displaying a higher prevalence of endocrine
diagnosis after a TBI diagnosis compared to male subjects.
Frontiers in Neurology | www.frontiersin.org 4 January 2020 | Volume 10 | Article 1410
Ortiz et al. Pediatric TBI and Endocrine Dysfunction
FIGURE 2 | Female subjects show a higher incidence, and an early age of onset, of hypothalamic-pituitary disorder following TBI compared to male subjects. (A)
Male and female patients with a TBI diagnosis and subsequent endocrine diagnosis were indexed by age, as a fraction of the total number of subjects in each group.
The lines represent male (n = 179; blue) and female (n = 319; red) age of each patient when they were diagnosed with a TBI, and the dots tracking along the x-axis
from the line indicate male (blue) and female (red) age at the time of their first endocrine diagnosis. (B) Endocrine diagnosis incidence rates after TBI were calculated
for male/female patients in blocks of 4-year age groups, with children older than 0 and ≤4 years old in the first block, followed by children >4 years old and ≤7.5
years old in the second block, etc. Female subjects diagnosed with a TBI (red line) were more likely to have a central endocrine diagnosis at an earlier age compared
with male subjects diagnosed with a TBI (blue line). The overall incidence of endocrine dysfunction peaked between ages 7 and 11. This is driven by the higher overall
incidence of post-TBI endocrine diagnoses in female patients, compared to male patients, whose incidence peaks between ages 11 and 15. Incidence rate was
calculated as the number of new cases per year of endocrine diagnoses in TBI patients divided by the cumulative population of TBI patients. (C) Data stratified by
male/female indicated female patients showed a shorter time gap between diagnosis of TBI and subsequent endocrine diagnosis compared with male subjects, but
not necessarily reflect the onset of undiagnosed symptoms.
Overall, both incidence and prevalence of endocrine diagnosis
following a TBI diagnosis peaked between ages 7–11, roughly
within 2 years of the initial TBI diagnosis. Additionally, by using
data from over 600,000 Arizona pediatric patients per year, we are
the first to successfully estimate the epidemiology, relative risk,
odds ratio, and number needed to harm of developing a central
endocrinopathy after sustaining a TBI in Arizona Medicaid
pediatric patients.
Mechanisms of Endocrine Dysfunction
The exact mechanisms behind endocrine dysfunction following
pediatric TBI are unknown, but may be attributed to direct
damage to the hypothalamus or pituitary gland. Together, the
hypothalamus and pituitary are an integral system in regulating
neuronal and hormonal function. The pituitary gland is regulated
by a centrally located collection of neurons in the hypothalamus.
The hypothalamus secretes precursors and hormones that
travel through the hypophyseal portal blood system to act
on receptors in the pituitary. The pituitary gland is a major
endocrine gland that secretes hormones necessary for normal
physiologic functioning such as growth hormone (GH), thyroid
stimulating hormone (TSH), adrenocorticotropic hormone
(ACTH), prolactin (PRL), luteinizing hormone (LH), follicle
stimulating hormone (FSH), anti-diuretic hormone (ADH), and
oxytocin. Injury to either the hypothalamus or pituitary gland
due to TBI has been shown, in both pre-clinical and clinical
studies, to promote endocrine dysfunction due to imbalance in
the hormones regulated by these structures (14, 31–35).
Mechanically, the forces of a TBI can selectively damage the
hypothalamus and/or the pituitary gland due to their location
close to the base of the skull. The pituitary sits at the base of
the brain, encapsulated by the hypophyseal fossa, the innermost
aperture of the sella turcica, a small cavity within the sphenoid
bone of the human skull. It is because of this position in the
skull that the pituitary is susceptible to mechanical injury from
the impact of blunt force head trauma. Indeed, early studies
assessing pituitary damage following TBI found that necrosis in
the pituitary gland occurred after injury in patients that had died
from TBI (36). More recent studies confirmed that cell death,
vascular compromise/hemorrhage, and diffuse axonal injury can
result from TBI and lead to damage of the pituitary [reviewed
in (37)]. Moreover, a recent study found that individuals who
sustained a skull fracture as a result of TBI had the highest rate
of pituitary dysfunction after a 1-year follow up (38). As such,
the impact forces that occur during a TBI event may directly
damage the pituitary or hypothalamus. Without case details on
the type and severity of injury, compounded by the majority of
TBI diagnosis codes as head injury—unspecified, the relationship
between mode of TBI and pituitary or hypothalamus damage
cannot be determined. Future population studies with access to
imaging findings could uncover this important relationship.
Prevalence of Endocrine Diagnosis
Following a TBI Diagnosis in the Literature
Studies have reported long-term hypopituitarism in the range
of 11–69% for TBI survivors, and endocrinopathies have
become increasingly recognized over the past couple decades
as a consequence of TBI (7, 20, 39). In 2005, the International
Consensus Guidelines published screening guidelines for
hypopituitarism after TBI in adults, recommending pituitary
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TABLE 4 | Top 10 reported ICD-9 codes for TBI-related diagnoses, and 14 ICD-9
codes for endocrine related diagnoses.
ICD-9
code
Description Number
of
patients
Frequency
(%)
TBI-RELATED
959.01 Head injury; unspecified 96,421 66.4
850.00 Concussion with no loss of
consciousness
10,446 7.2
850.90 Concussion; unspecified 7,850 5.4
850.50 Concussion with loss of
consciousness of unspecified
duration
3,865 2.7
802.00 Fracture of face bones 3,822 2.6
850.11 Concussion; with loss of
consciousness of 30min or less
3,562 2.5
854.01 Intracranial injury of other and
unspecified nature without mention of
open intracranial wound; with no loss
of consciousness
2,392 1.6
800.01 Closed fracture of vault of skull
without mention of intracranial injury;
with no loss of consciousness
1,489 1.0
802.80 Closed fracture of other facial bones 1,109 0.8
801.01 Closed fracture of base of skull
without mention of intra cranial injury;
with no loss of consciousness
943 0.6
ENDOCRINE-RELATED
259.10 Precocious sexual development and
puberty; not elsewhere classified
5,334 59.4
253.30 Pituitary dwarfism 856 9.5
259.00 Delay in sexual development and
puberty; not elsewhere classified
731 8.1
253.50 Diabetes Insipidus 407 4.5
253.20 Panhypopituitarism 405 4.5
253.10 Other and unspecified anterior
pituitary hyperfunction
319 3.6
253.80 Other disorders of the pituitary and
other syndromes of
diencephalohypophyseal origin
244 2.7
253.40 Other anterior pituitary disorders 177 2.0
253.90 Unspecified disorder of the pituitary
gland and its hypothalamic control
172 1.9
253.60 Other disorders of neurohypophysis 147 1.6
256.39 Other ovarian failure 118 1.3
253.70 Latrogenic pituitary disorders 64 0.7
256.31 Premature menopause 5 0.05
628.1 Infertility; female; of pituitary
hypothalamic origin
0 0
function screening for all patients with moderate (Glasgow
coma score 9–12) to severe TBI (Glasgow coma score 3–8)
(20). Although the hypothalamic-pituitary axis regulates normal
childhood development, relatively few studies focus on pediatric
patients, and no endocrine dysfunction screening guidelines exist
for children diagnosed with a TBI. Retrospective and prospective
studies report variable rates of hypopituitarism after childhood
TBI (18, 19, 21–23). Among retrospective cohort studies that
have investigated new-onset endocrine dysfunction after TBI
in children (20, 22, 23), our study is unique in that it contains
the largest number of patients in the analysis, and it is also the
only study to investigate post-TBI endocrine dysfunction in a
large state-wide dataset. Regardless, the prevalence of endocrine
dysfunction in the first 6 months after TBI [4–86%; (21, 22, 24)],
and at 1–5 years after TBI [10–38%; (18, 19, 23, 37)] in children
as currently reported in the literature is not instructive due
to the large variability in prevalence. The variability in overall
prevalence of pituitary dysfunction after TBI may be due to
under recognition by caregivers and health-care providers due
to protracted, subtle, and non-specific signs, as well as a broad
differential diagnosis (40). Also, more than one endocrine
pathway may be disrupted after TBI, further confounding the
symptomatology and presentation of these patients.
The majority of endocrine dysfunction post-TBI in pediatric
patients are GH deficiencies (21–31%), but children can also
experience central adrenal deficiency, diabetes insipidus, central
hypothyroidism, hypogonadotropic hypogonadism, and elevated
prolactin reported between 6 months to a year after TBI (41).
It is known that in adults, endocrine dysfunction may present
up to 5 years after the initial TBI, suggesting the need for
continuous endocrine monitoring of TBI survivors (42, 43).
Moreover, recovery of pituitary function can occur in up to 50%
of adult patients with major hormonal deficiencies diagnosed at
3 months post-injury (7, 20, 44).
Importantly, unrecognized hypopituitarism can elevate
risk for diabetes, delayed or absent puberty, short stature,
metabolic syndrome, adrenal insufficiency, and other endocrine
dysfunctions, that can significantly affect patients’ quality of
life. Screening for endocrine deficiencies in susceptible patients
and initiating appropriate hormone replacement therapy may
prevent these sequelae and improve the prognosis for recovery.
For TBI patients, endocrine dysfunction may be prevented,
or the prospect for recovery may be improved, through the
application of a systematic screen for endocrine dysfunction
and the administration of appropriate, well-studied, and well-
tolerated hormone replacement therapy. If TBI occurs near
period of elevated growth velocity (10–12 years of age for
girls; 13–15 years of age for boys), then patients may risk short
stature throughout life. Thus, childhood TBI should initiate
regular endocrine surveillance, with accurate height and weight
measurements, and blood tests and symptom monitoring every
6 months in the first year and yearly thereafter.
Risk factors of hypothalamic-pituitary disorders after TBI
are controversial, without definitive relationships between injury
factors and hypopituitarism (26, 45, 46). Importantly, TBI need
not be severe to lead to endocrine dysfunction, since repeated
less severe TBIs disrupt endocrine function (47). In the current
study, the dataset lacked indicators of injury severity and a
limited number of TBI ICD-9 codes were used, which prevented
analysis of a relationship between TBI severity and hypothalamic-
pituitary disorder.
Overall, individuals that suffer pediatric and adult TBI
may experience hormonal deficits for many years, with a
wide range of symptom expression in these patients. Post-TBI
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endocrinopathies and hypothalamic-pituitary disorders must be
considered in the differential diagnosis of any patient with a
history of head trauma, regardless of age at injury, mechanism, or
severity. Additional large cohort studies, such as ours, are needed
to detail the prevalence of endocrine dysfunction following TBI
in order to guide clinical decisions.
Benefits and Limitations of Health Care
Terminologies
For this study, we used ICD-9 diagnostic codes associated with
TBI and central endocrine disorders to develop inclusion criteria.
ICD-9 and Current Procedural Terminology (CPT) billing codes
for reimbursement are a vital part of health-care operations
(48, 49). These terminologies or codes are generally specific to a
particular disease, syndrome, or diagnosis of each patient. These
codes are entered into hospital records for every patient visit,
regardless of acuity. For example, a patient at her 11th office visit
for GH deficiency will have the relevant diagnostic code entered,
despite it being the 11th visit for this chronic condition. The
physician will also submit a billing code along with the diagnostic
code for GH deficiency. Billing codes are coupled with diagnostic
codes to help health insurance companies determine the reason
for the visit as well as the appropriate reimbursement rate. ICD-
9 codes have inherent flaws both with the level of detail and
selection of codes by the physician. Selection bias is demonstrated
by the predominant TBI ICD-9 code in AHCCCS as 959.01
(Head Injury: unspecified), when there are over 400 other codes
to select. It is suspected that the ICD-9 code for “Head Injury:
unspecified” and the code for “concussion” may represent a mix
of all TBI types which limited our ability in the current study
to stratify data and analyze if a specific mechanism of TBI was
associated with a higher frequency of central endocrinopathies.
Moreover, the use of ICD-9 codes limits interpretation and
access to information regarding previous neurological disorders
and/or prescribed medications, where steroids and medication
for attention deficit hyperactivity disorder may increase risk for
endocrine disorders.
Another limitation of our sample is that our data are
derived from the Medicaid population of Arizona. Medicaid
is the Federal and State program within the United States
that subsidizes the cost of medical care for individuals and
families with low income and limited resources. In Arizona, the
Arizona Health Care Cost Containment Service (AHCCCS) is
the Medicaid program, funded by both the Federal and State
government, which provides medical insurance coverage for
individuals and families. In the year 2011, a half-way point
of the years sampled in our study (2008–2014), in order to
qualify for this Medicaid program (AHCCCS) individuals were
required to meet the following requirements: must be an Arizona
resident, must be a United States citizen or qualified immigrant,
must have or have applied for a social security number, and
must be under the income limit. In 2011, the income limit
of a family’s income was required to be at or below 133% of
the federal poverty level of $22,350/year for a family of four.
As such, this sample population represents a unique group of
individuals and may not generalize to the entire population.
These shortcomings are inherent in any large database, however
they are recognized and assumed to be equal among age and
male/female patients.
Other limitations of the study include patients who were
missed due to the nature of data collection in AHCCCS, due
to underreporting of symptoms of endocrine disorders, and due
to the large number of patients who do not report TBI. Our
data show that most endocrine diagnoses occur in the 2 years
following a TBI diagnosis. As such, there is a large cohort of
individuals who experience a TBI event from the ages of 15–
18 and possibly later go on to develop an endocrine disorder
in the next years, but the AHCCCS database does not include
children over the age of 18 years. As such, we may have missed
patients who suffered a TBI in their late teens and later developed
an endocrine disorder over the 18-year-old exclusion criteria.
Moreover, some studies report that endocrine disorders during
this age range may be underreported or not recognized as a
TBI-induced endocrinopathy (50). Additionally, TBI can often
go unreported (51, 52), especially when they are mild injuries.
However, in the adult literature it has been shown that even
mild injuries can lead to dysfunctions of the endocrine system
(37, 53). Therefore, these patients may also have been missed in
our cohort analysis.
Significance and Rational for the Research
Question
Despite the wide-ranging reports on pediatric TBIs affecting
endocrine function, there is little published epidemiological
data analyzing large cohorts of patients to identify correlations
with male and female patients and age. Additionally, assessing
endocrine function is not commonly considered in a clinician’s
differential diagnosis for a patient presenting to the office
after TBI, nor is a history of TBI routinely asked for in a
patient presenting with fatigue, weight gain, obesity, delayed
puberty, and growth stunting. Our study, and others like it,
help emphasize the importance of screening for endocrine
dysfunction through diligent history taking and serum endocrine
analysis in all patients with a history of pediatric TBI. Moreover,
predictive measures are needed in order to better determine
which children should undergo further endocrine evaluation
after TBI. In order to better care for patients, it is of
high importance to develop standard protocols to accurately
diagnosis endocrine dysfunction following TBI. Results from
this project will help to increase awareness among pediatricians,
pediatric endocrinologists, pediatric neurologists, and other
clinicians treating children with TBIs, of the incidence and
risks of endocrine disorders among TBI survivors. Patients
can present with central, new-onset endocrinopathies days to
years after TBI, and further assessments of risk-factors and
characteristics that contribute to endocrine dysfunction after TBI
are critical. Physicians must be aware of endocrine symptoms
after TBI and add TBI-induced central endocrinopathies to their
differential diagnosis when treating a patient with a history
of TBI.
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